Showing 8321-8330 of 8688 results for "".
- OPTiM Trial Results: New Immunotherapy Study in Melanomahttps://practicaldermatology.com/news/20130409-optim_trial_results_new_immunotherapy_study_in_melanoma/2459569/Results from the Oncovex (GM-CSF) Pivotal Trial in Melanoma (OPTiM) show that a genetically modified version of herpes simplex virus type 1, designated talimogene laherparepvec (T-VEC), shrank melanoma in patients who were in the late stages of the disease. The T-VEC virus works through direct dest
- Rosacea Hinders Social Experiences For More Than 16 Million Americanshttps://practicaldermatology.com/news/20130409-rosacea_hinders_social_experiences_for_more_than_16_million_americans/2459570/Roughly half of rosacea patients refuse certain foods and drinks for fear of triggering a rosacea flare-up. That's according to numbers from the National Rosacea Society (NRS), which designated the month of April as Rosacea Awareness Month to alert the public to the early warning signs of rosacea. T
- Novan Therapeutics: Nitric Oxide May Inhibit Skin Steroidogenesis Locallyhttps://practicaldermatology.com/news/20130408-novan_therapeutics_nitric_oxide_may_inhibit_skin_steroidogenesis_locally/2459571/Novan Therapeutics reports topical nitric oxide-based therapies may reduce androgen levels in the skin by locally inhibiting skin steroidogenesis. The targeted reduction of androgens in the skin could lead to first-in-class local antiandrogen products to treat acne and androgenic alopecia (male patt
- Obagi Fate Uncertain as New Details Emergehttps://practicaldermatology.com/news/20130403-obagi_fate_uncertain_as_new_details_emerge/2459573/Following a bidding war with rival Merz Pharma Group, Valeant Pharmaceuticals appears set to acquire Obagi Medical Products. Valeant's original offer came in March, when the company announced that it would acquire Obagi at $19.75 per share, in a deal worth approximately $344 million. Then, in early
- Merz Makes Offer for Obagihttps://practicaldermatology.com/news/20130402-merz_makes_offer_for_obagi/2459576/With an unexpected $383.5 million bid, Merz Pharma Group formally proposed to acquire Obagi Medical Products, outdoing rival Valeant's bid for Obagi announced late last month and reported in yesterday's edition of DermWire. Merz sent a letter to Obagi Medical Products Inc.'s board offering to buy al
- New Survey Finds Social Media is a Major Influence on Elective Surgeryhttps://practicaldermatology.com/news/20130327-new_survey_finds_social_media_is_a_major_influence_on_elective_surgery/2459578/Social media is leading consumers to have a more self-critical eye, according to a new survey by the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS). The annual poll of the organization's board-certified facial plastic surgeons found a 31 percent increase in requests for surge
- Skin Cancer Foundation Inducts Dr. Amy Forman Taub into its Amonette Circlehttps://practicaldermatology.com/news/20130327-skin_cancer_foundation_inducts_amy_forman_taub_md_into_its_amonette_circle/2459579/Amy Forman Taub, MD, was recently inducted into the Skin Cancer Foundation's Amonette Circle at the American Academy of Dermatology Annual Meeting in Miami, FL. Amonette Circle is a lifetime membership comprised of physicians who make an outstanding commitment to The Skin Cancer Foundation's mission
- Merz to Absorb Costs of New Excise Tax on Certain Medical Deviceshttps://practicaldermatology.com/news/20130321-merz_to_absord_costs_of_new_excise_tax_on_medical_devices/2459580/Merz Aesthetics announced that it does not intend to raise prices on medical devices, despite the new excise tax on the sale of certain medical devices of about 2.3 percent now going into effect, per the Patient Protection and Affordable Care Act. In a statement to clients and potential clients, Mer
- District Court Judge Blocks Marketing and Sales of RevitaLashhttps://practicaldermatology.com/news/20130320-district_court_judge_blocks_marketing_and_sales_of_revitalash/2459584/A district court judge recently prohibited Athena Cosmetics, Inc. from marketing or selling its RevitaLash Advanced Eyelash Conditioner in the United States. The ruling came as part of a civil lawsuit brought by Allergan Inc., maker of Latisse, in which the company claimed unfair competition in the
- Survey: Scars and Stretch Marks Significantly Impact Women's Confidencehttps://practicaldermatology.com/news/20130318-survey_scarsstretch_marks_have_significant_negative_impact_womens_confidence/2459586/A new survey reveals that men and women have complex and often differing feelings about how their skin Imperfections impact their appearance and confidence. In the Mederma® Wear Your Skin Proudly™ survey, 34 percent of women reported that the appearance of scar(s) and/or stretch marks would make the